Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Rezolute, Inc. RZLT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.86
+120.7%

Rezolute, Inc. (RZLT) is a Biotechnology company in the Healthcare sector, currently trading at $3.56. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is RZLT = $8 (+120.7% upside).

Valuation: RZLT trades at a trailing Price-to-Earnings (P/E) of -4.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.2.

Net income is $74M (loss), growing at -22.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $162M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 14.37 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $175M.

Analyst outlook: 12 / 12 analysts rate RZLT as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$7.86
▲ 120.72% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Rezolute, Inc., the average price target is $7.86, with a high forecast of $20.00, and a low forecast of $2.00.
Highest Price Target
$20.00
Average Price Target
$7.86
Lowest Price Target
$2.00

RZLT SharesGrow Score Overview

66/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 88/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RZLT

✓
VALUE Pass
88/100
RZLT trades at a trailing Price-to-Earnings (P/E) of -4.3 (S&P 500 average ~25). Forward PEG 1.2 — ~moderate (~1.5). Analyst consensus target is $8, implying +124.7% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
RZLT: +0%/yr revenue is, -22.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RZLT: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 14.37 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
RZLT: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 12 / 12 analysts rate RZLT as buy (100%). Analyst consensus target is $8 (+124.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.07-11.457
Volume872.14K
Avg Volume (30D)2.85M
Market Cap$340.78M
Beta (1Y)0.66
Share Statistics
EPS (TTM)-0.98
Shares Outstanding$76M
IPO Date2013-01-14
Employees64
CEONevan Charles Elam
Financial Highlights & Ratios
EBITDA$-79.86M
Net Income$-74.41M
Operating Income$-79.89M
Total Cash$167.86M
Total Debt$1.62M
Net Debt$-92.49M
Total Assets$175.49M
Price / Earnings (P/E)-3.6
Analyst Forecast
1Y Price Target$5.00
Target High$20.00
Target Low$2.00
Upside+40.4%
Rating ConsensusBuy
Analysts Covering12
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS76200L3096

Price Chart

Track all markets on TradingView
RZLT
Rezolute, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.07 52WK RANGE 11.46

People Also View

LRMR
LRMR
Larimar Therapeutics, Inc.
$4.87
+0.21%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
 CLNN
CLNN
Clene Inc.
$6.68
+3.01%
 RPHM
RPHM
Reneo Pharmaceuticals, Inc.
$18.20
+952.02%
 FRLN
FRLN
Freeline Therapeutics Holdings plc
$6.49
+0.15%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message